Dawn Biopharma led a €16m Series A extension round in Adcendo.

Dawn Biopharma, a platform controlled by KKR, led a €16m Series A extension round in Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates for the treatment of cancers with a high unmet medical need, with participation from Novo, Ysios Capital, RA Capital Management, HealthCap, Gilde Healthcare and Pontifax Venture Capital. “This financing underscores the confidence that our investors have in Adcendo’s capabilities and potential to develop highly innovative ADC cancer therapies to provide treatment options for cancer patients with high unmet medical needs. We are extremely pleased to welcome Iyona to the Adcendo Board of Directors, as she brings a wealth of experience in supporting and advancing early and clinical stage biotech companies,” Michael Pehl, Adcendo CEO.